Analysts Set ABIVAX Société Anonyme (NASDAQ:ABVX) Target Price at $36.50

ABIVAX Société Anonyme (NASDAQ:ABVX) has earned an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $36.50.

Separately, Laidlaw initiated coverage on ABIVAX Société Anonyme in a research note on Monday, July 29th. They issued a “buy” rating and a $48.00 target price on the stock.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets bought a new stake in shares of ABIVAX Société Anonyme during the 1st quarter worth about $81,000. Capstone Investment Advisors LLC grew its holdings in ABIVAX Société Anonyme by 9.0% during the first quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company’s stock valued at $900,000 after purchasing an additional 5,199 shares during the last quarter. Kennedy Capital Management LLC grew its holdings in ABIVAX Société Anonyme by 35.3% during the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock valued at $1,718,000 after purchasing an additional 31,331 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its stake in shares of ABIVAX Société Anonyme by 18.2% in the first quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock worth $12,113,000 after buying an additional 131,414 shares during the last quarter. 47.91% of the stock is currently owned by institutional investors.

ABIVAX Société Anonyme Stock Performance

ABIVAX Société Anonyme stock opened at $10.45 on Thursday. ABIVAX Société Anonyme has a 12 month low of $7.99 and a 12 month high of $17.02. The company’s fifty day simple moving average is $11.15 and its 200-day simple moving average is $12.80.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.